[1] 国家卫生计生委合理用药专家委员会. 冠心病合理用药指南[J]. 中国医学前沿杂志,2016,8(6):19-108. [2] 姚震,陈林. 我国心血管疾病现状与展望[J]. 海南医学,2013,24(13):1873-1876. [3] 易德青. 血脂异常的危险因素及脂代谢关联基因相关性研究[D]. 汕头大学,2011. [4] 郑炜平,陈海峰.阿托伐他汀对高血压合并高低密度脂蛋白胆固醇血症患者肾功能的影响[J]. 中华高血压杂志,2016,24(1):56-60. [5] 郑雅俊.ABCB1、ABCA1基因SNPs与阿托伐他汀调脂疗效的关系[D]. 皖南医学院,2014. [6] HAN S H, KANG E W, YOON S J, et al. Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis [J]. Nephrol Dial Transplant,2011, 26(11): 3722-3728. [7] PRADO Y,SAAVEDRA N,ZAMBRANO T,et al. Slco1b1c. 388a>g polymorphism is associated with hdlc levels in response to atorvastatin in chilean individuals[J]. Int J Mol Sci,2015,16(9):20609-20619. [8] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J]. 中华心血管病杂志,2007,35:390-418. [9] HAO F F, DU Y M, LAI Y. Advance in search for gene polymorphisms on pharmacokinetics of atorvastatin [J]. Chin J New Drug Clin Rem, 2012, 31(3): 128-133. [10] LOSCHER W,KLOTZ U,ZIMPRICH F,et al. The clinical impact of pharmacogenetics on the treatment of epilepsy[J]. Epilepsia,2009,50(1):1-23. [11] ZINTZARAS E. Is there evdience to claim or deny association between variants of the multidrug resistance gene(MDR1 or ABCB1)and inflammatory bowel disease[J]. Inflamm Bowel Dis,2012,18(3):562-572. [12] WU H,KANG H,LIU Y,et al. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes[J]. J Cancer Res Clin Oncol,2012,138(9):1449-1462. [13] HAMIDOVIC A,HAHN K,KOLESAR J. Clinical significance of ABCB1 genotyping in oncology[J]. J Oncol Pharm Pract,2010,16(1):39-44. [14] KIM H J,HWANG S Y,KIM I H,et al. Association between genetic polymorphism of multidrug resistance 1 gene and sasang constitutions[J]. Evid Based Complement Altemat Med,2009,66(1):73-80. [15] KAJINAMI K,BROUSSEAU M E,ORDOVAS J M,et al. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a genderspecific manner[J].Am J Cardiol,2004, 93: 1046-1050. [16] YUAN Z, LI X H, HUANG S B, et al. The molecular mechanism of actin of OATP1B1 and CYP3A4 genetic polymorphism on the metabolism and transport of atorvastatin [J]. Chin Hosp Pharm J, 2013, 33(13): 1035-1041. [17] HE A X, SHI L, ZHAO J S.Advances in search for pharmacogenomics of atorvastatin[J]. Chin J Clin Pharmacol,2011,27(11):888-891. [18] BANDDUR S, PETRASEK J, HRIBOVA P, et al. Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients[J]. Transplantation,2008,86(9):1206-1213. |